Five new teams selected to take on cancer’s toughest challenges
Today we’re excited to announce the five new global teams that have been selected to each receive up to $25m in Cancer Grand Challenges funding over five years to take on four of cancer’s toughest challenges. In March 2023, we announced…
Josephine Bunch reflects on a new way to map cancer.
In taking on our 3D Tumour Mapping challenge, the Cancer Grand Challenges Rosetta team has curated a suite of mass spectrometry imaging (MSI) techniques that can…
What can studying non-cancerous tissue from people with cancer teach us about a tumour? Dr Peter Campbell (Sanger Institute, Cambridge, UK), co-investigator of the team taking on our Unusual Mutation Patterns challenge…
Common infection could be one driver of colorectal cancer rise in younger adults, according to findings from members of the team taking on our Microbiome challenge.
Data collected by researchers at the Johns Hopkins…
On 16 June 2022, we announced 4 new Cancer Grand Challenges teams taking on some of the toughest challenges in cancer research. Here, meet the NexTGen team receiving $25m to take on the Solid Tumors in Children…
On 16 June 2022, we announced four new Cancer Grand Challenges teams taking on some of the toughest challenges in cancer research.
Here, meet the CANCAN team receiving $25m to take on the Cachexia challenge.
Many…
On 16 June 2022, we announced four new Cancer Grand Challenges teams taking on some of the toughest challenges in cancer research. Here, meet the PROMINENT team receiving $25m to take on the Normal Phenotypes challenge…
Today we announce the four new teams selected to each receive $25m Cancer Grand Challenges funding to take on some of the toughest challenges in cancer research.
Representing a total investment of $100m, these are…
Cancer Grand Challenges scientists and collaborators have created the first map of the major chromosomal changes that occur during cancer. This information could help physicians better understand how individual tumours…
Today, the team taking on our Lethal vs. Non-Lethal challenge shared new findings that could change management and treatment for people with ductal carcinoma in situ (DCIS).
To find out more about the clinical…